The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Chronic Proton Pump Inhibitor Therapy and the Risk of Colorectal Cancer
Open accessAbstract
Background & aims Chronic acid suppression by proton pump inhibitor therapy can lead to hypergastrinemia. Because existing evidence suggested an association between hypergastrinemia and colorectal cancer, we examined whether long-term proton pump inhibitor use is associated with an increased risk of colorectal cancer in a population-representative cohort.Methods We conducted a nested case-control study among patients 50 years of age and older and with > or =5 years of colorectal cancer-free initial follow-up in the General Practice Research Database (1987-2002) from the United Kingdom. Cases consisted of all patients with an incident diagnosis of colorectal cancer. Using incidence density sampling, up to 10 controls were matched with each case on practice site and both duration and calendar time of follow-up before the index date. The primary exposure of interest was > or =5 years of cumulative proton pump inhibitor therapy. We assessed the presence of duration-response and dose-response effects.Results We identified 4432 incident colorectal cancer cases and 44,292 controls. The adjusted odds ratio for > or =5 years of proton pump inhibitor exposure was 1.1 (95% confidence interval, 0.7-1.9). Among high-dose proton pump inhibitor users (ie, > or =1.5 defined daily doses/day), there was a nonstatistically significant trend toward an increased risk with increasing duration of use (test for trend, P = .2). However, patients with pernicious anemia were not at increased risk for colorectal cancer (adjusted odds ratio, 0.9; 95% confidence interval, 0.6-1.3).Conclusions Long-term proton pump inhibitor therapy at a regular dose is not associated with a significantly increased risk of colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, it is fundamental to highlight that many studies over the years have not found a direct correlation between PPI use in clinical practice and an increased risk of CRC[154-156].”
From Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified (2019) · cites this paper as [154]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prophylactic aspirin and risk of peptic ulcer bleeding
Weil, J., Colin-Jones, D. G., Langman, M. J. S., Lawson, D. H., Logan, R., Murphy, M. S., Rawlins, M. D., Vessey, M. P., & Wainwright, P. (1995) · BMJ · doi:10.1136/bmj.310.6983.827 · Cited by 563
Klinkenberg–Knol, E. C., Nelis, F. G., Dent, J., Snel, P., Mitchell, B., Prichard, P. J., Lloyd, D., Havu, N., Frame, M. H., Román, J., et al. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70135-1 · Cited by 533
The Read clinical classification.
Chisholm, J. (1990) · BMJ · doi:10.1136/bmj.300.6732.1092 · Cited by 504
Long-Term Treatment with Omeprazole for Refractory Reflux Esophagitis: Efficacy and Safety
Klinkenberg–Knol, E. C., Festen, H. P. M., Jansen, J. B. �. �., Lamers, C. B. H. W., Nelis, F., Snel, P., Luckers, A., Dekkers, C. P. M., Havu, N., & Meuwissen, S. G. M. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-3-199408010-00001 · Cited by 422
Biased Selection of Controls for Case-Control Analyses of Cohort Studies
Lubin, J. H., & Gail, M. H. (1984) · Biometrics · doi:10.2307/2530744 · Cited by 414
García Rodríguez, L. A., & Huerta-Alvarez, C. (2001) · Epidemiology · doi:10.1097/00001648-200101000-00015 · Cited by 359
Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients
Yang, Y., Hennessy, S., & Lewis, J. D. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.07.011 · Cited by 350
Self-citationLewis, J. D., Bilker, W. B., Weinstein, R. B., & Strom, B. L. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1115 · Cited by 342
Self-citationGrowth-Promoting Effects of Glycine-Extended Progastrin
Seva, C., Dickinson, C. J., & Yamada, T. (1994) · Science · doi:10.1126/science.8023165 · Cited by 337
Long-term omeprazole therapy in peptic ulcer disease: Gastrin, endocrine cell growth, and gastritis
Lamberts, R., Creutzfeldt, W., Strüber, H. G., Brunner, G. H. G., & Solcia, E. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90344-c · Cited by 322
Flagged first, then by citations
1 of the 53 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–125 of 125
Liu, Q., Wang, X., Engstrand, L., Sadr‐Azodi, O., Fall, K., & Brusselaers, N. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-079591 · Cited by 1
de Micheaux, S. L. (2014) · Cited by 1
Gastric acid-related disorders and drugs: An epidemiological perspective
van Soest, E. M. (2008) · Cited by 1
Chronic Proton Pump Inhibitor Therapy and the Risk of Colorectal Cancer
Katzka, D. A. (2008) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(08)79136-0 · Cited by 1
The use of a proton pump inhibitor does not increase the risk of colorectal cancer: a meta- analysis
Liu, R., & Shao, Y. (2020) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-2878 · Cited by 1
Obeidat, A. E., Monti, G. K., Choi, H., & Acoba, J. D. (2023) · Cureus · doi:10.7759/cureus.38707 · Cited by 1
“Multiple observational studies and meta-analyses conducted across different populations have failed to report any association between long-term PPI and the risk of CRC [10-18].”
BackgroundEfectos a largo plazo de los inhibidores de bomba de protones
García, Á. B., Román, O. P., & Sáez, M. L. (2012) · Revista Andaluza de Patología Digestiva · Cited by 1
Micro-elimination of hepatitis C virus infection - the beginning of the end
Huiban, L., Stanciu, C., Sfarti, C. V., Muzica, C. M., Cuciureanu, T., Zenovia, S., Frunzuc, G., Damian, I., & Trifan, A. V. (2020) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-3028 · Cited by 1
Association between the chronic use of gastric acid suppressants and high‐risk colorectal polyps
Shiratori, Y., Ikeya, T., Ishii, N., Yamamoto, K., Honda, T., Hasatani, K., Yoshida, N., Nishida, T., Sumiyoshi, T., Kiyotoki, S., et al. (2021) · JGH Open · doi:10.1002/jgh3.12503 · Cited by 1
O czym warto pamiętać, stosując przewlekle inhibitory pompy protonowej?
Wocial, T. (2013) · DOAJ (DOAJ: Directory of Open Access Journals)
3. Risk of Upper Gastrointestinal Bleeding during Clopidogrel Therapy with or without a PPI
Yasuda, H. (2011) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.42.369
Mühlhaupt, B., Schöfl, R., Rösch, T., Bauerfeind, P., Schwizer, W., Wirth, H.-P., Rogler, G., & Fried, M. (2009) · Die Gastroenterologie · doi:10.1007/s11377-008-0255-1
[Adverse effects of proton pump inhibitors].
Doweck, J. (2009) · PubMed
PPIs Don’t Increase Risk for Colorectal Cancer
Rex, D. K. (2007) · Journal watch · doi:10.1056/jg200710050000002
Proton Pump Inhibitor Use and Risk of Colorectal Cancer: A Population-Based, Case–Control Study
Katzka, D. A. (2008) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(08)79135-9
Qu, B. (2017) · Archives of Clinical Gastroenterology · doi:10.17352/2455-2283.000034
“However, only a previously study suggested that PPI use might be modestly associated with CRC risk [53,54].”
Kristóf, T., Orosz, P., Nagy, G., & Minik, K. (2006) · Zeitschrift für Gastroenterologie · doi:10.1055/s-2006-943431
Proton Pump Inhibitor Controversies
Jaworek, A. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-48890-1_31
Proton Pompa İnhibitörlerinin Uzun Dönem Kullanımındaki Etkileri
İspiroğlu, M., Gişi, K., & Kantarçeken, B. (2020) · Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi · doi:10.17517/ksutfd.690248
Obeidat, A. E., Monti, G. K., Choi, H., & Acoba, J. D. (2021) · Research Square · doi:10.21203/rs.3.rs-796911/v1
Obeidat, A. E., Monti, G. K., Choi, H., & Acoba, J. D. (2022) · Research Square · doi:10.21203/rs.3.rs-796911/v2
Ramnarace, R., & Dalton, H. R. (2010) · Side effects of drugs annual · doi:10.1016/s0378-6080(10)32036-8
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00955-0
Vergleich zwischen den verschiedenen Protonenpumpenhemmern
Kostner, S. (2011) · Zeitschrift für Allgemeinmedizin · doi:10.1007/bf03652212
de Brito, A. S., do Nascimento, A. N., Fonseca, F. L. A., Fioroto, A. M., Petri, G., & Nascimento, R. P. (2026) · ACS Omega · doi:10.1021/acsomega.6c04757
Metadata
- Authors
- Yang, Y., Hennessy, S., Propert, K., Hwang, W., Sedarat, A., & Lewis, J. D.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Yang, Yu–Xiao
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2007-09
- Volume
- 133
- Issue
- 3
- Pages
- 748-754
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2154036780
- Cited by
- 125
- References
- 53
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 7 · 2022: 1 · 2021: 7 · 2020: 16 · 2019: 4 · 2018: 5 · 2017: 7 · 2016: 2 · 2015: 5 · 2014: 3 · 2013: 9 · 2012: 8
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K08DK062978)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
- Keywords
- proton pump inhibitors, colorectal cancer, hypergastrinemia, acid suppression, long-term drug use, pernicious anemia, dose-response relationship, cancer risk
- MeSH terms
- Adenocarcinoma, Aged, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Gastroesophageal Reflux, United Kingdom, Humans, Longitudinal Studies, Male, Middle Aged, Risk Factors, Time Factors, Colorectal Neoplasms, Case-Control Studies, Proton Pump Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
